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Abstract
Venous thromboembolism (VTE) affects more than 300,000 people in the United States each year. 
However, it has been estimated that current diagnostic testing fails to identify pro-thrombotic risk 
in 50% of VTE patients. This report examines the relationship between levels of the pro-coagulant 
proteins factor VIII (FVIII), von Willebrand factor (VWF), and fibrinogen and risk of VTE in 
order to assess the impact of these novel risk factors. Data were collected from patients enrolled in 
the matched case-control Genetic Attributes and Thrombosis Epidemiology study. Crude and 
adjusted conditional logistic regression models were used to assess the impact of FVIII, VWF, and 
fibrinogen on risk of VTE. Before adjustment for independent predictors of VTE risk, high levels 
of FVIII, VWF, and fibrinogen were significantly associated with increased risk of VTE in both 
Blacks and Whites. After adjustment for ABO type, factor VII levels, hypertension, renal disease, 
recent surgery, diabetes, annual household income, alcohol use, and the other proteins of interest 
(FVIII , VWF, and/or fibrinogen), high FVIII and VWF levels were associated with increased risk 
of VTE in Blacks (OR: 1.97 (1.01-3.84) and 3.39 (1.58-7.27), respectively). High FVIII only was 
significantly associated with risk of VTE in Whites (OR: 2.35 (1.16-4.75)). High FVIII and VWF 
are independent risk factors for VTE in Blacks, and high FVIII levels are a risk factor for VTE in 
Whites. Future research into the inclusion of these protein levels in risk models for VTE could 
help identify persons at highest risk.
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Introduction
Venous thromboembolism (VTE) is estimated to affect 300,000-600,000 people in the 
United States each year.1 VTE is the third leading cause of cardiovascular death2, and it 
disproportionately affects Blacks.3 Because current diagnostic testing for VTE fails to 
identify underlying pro-thrombotic tendency in about 50% of patients, identification of 
novel risk factors for VTE is essential.4 Furthermore, several risk factors known to be 
associated with risk of VTE in Whites have been shown to have little impact on VTE risk in 
Blacks.5-7 Identification of risk factors that may explain these racial differences may prove 
important in preventing VTE and reducing associated health disparities.
Several reports have indicated that high levels of pro-coagulant proteins may be independent 
risk factors for VTE.8-12 Factor VIII (FVIII) circulates in plasma bound to von Willebrand 
factor (VWF) and is proteolytically cleaved during clot formation to yield activated FVIII 
which serves as a cofactor for the activation of Factor X (FX). Subsequently, activated FX 
serves as a cofactor for the conversion of prothrombin to thrombin, which acts on fibrinogen 
to form a fibrin clot. VWF stabilizes FVIII and provides an adhesive linkage between 
platelets and the subendothelium at sites of vascular injury. Elevated levels of FVIII have 
consistently been shown to be associated with risk of VTE, 8-10 while elevated levels of 
VWF and fibrinogen have not been consistently associated with an increased risk of 
VTE.8,11-14 Furthermore, ethnic differences in mean steady-state levels of these proteins 
have been reported, with Blacks having higher average levels of both FVIII and VWF.15,16 
FVIII, VWF, and fibrinogen, however, are acute phase reactants and are elevated in some 
conditions known to be risk factors for VTE. This study examines the relationship between 
pro-coagulant protein levels measured after VTE events in a group of VTE cases compared 
to protein levels measured in a group of control patients and risk of VTE in both Blacks and 
Whites after adjustment for covariates.
Materials and Methods
Study Population
The methods of the Genetic Attributes and Thrombosis Epidemiology (GATE) study have 
been described elsewhere.17 Briefly, GATE is an age, sex, and race frequency-matched 
case-control study conducted in Atlanta, Georgia from January 1997 to September 2005 
designed to identify risk factors for VTE. Cases (n=1145) were selected from patients 
presenting with a first or recurrent VTE at either Crawford Long Hospital or Emory 
University Hospital and were confirmed by medical record review. Controls (n=1309) were 
selected from an Emory Healthcare primary care clinic. This report was limited to Black and 
White cases and controls who were not currently receiving anticoagulant therapy, who had 
available FVIII, VWF, and fibrinogen data, and who had a FVIII level above 50 IU/dl 
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(n=1498). This project was approved by the Emory University and Centers for Disease 
Control and Prevention (CDC) Institutional Review Boards.
Laboratory Analyses
Blood samples were collected at the CDC laboratory (Atlanta, GA, USA). Samples were 
collected from controls upon recruitment and were collected from cases after completion of 
anticoagulant therapy. Samples were collected in siliconized evacuated glass tubes 
(Vacutainer, Becton Dickinsom and Company, Franklin Lakes, New Jersey, USA) 
containing 0.109M sodium citrate in a 1 to 9 volume ratio of citrate to blood. The tubes were 
centrifuged at 1,600 x g at 4 ºC for 20 minutes followed by a repeat centrifugation of the 
separated plasma using the same protocol. The resulting platelet-poor plasma was stored in 
0.5-mL aliquots at −70 ºC until use.
FVIII, Factor VII (FVII), activated partial thromboplastin time (APTT), and fibrinogen were 
measured on the STA coagulation analyzer (Diagnostica Stago, Parsippany, New Jersey, 
USA). FVIII clotting activity was measured using a one-stage assay (Diagnostica Stago) that 
employs silica as an activator. Results of the assay were expressed as IU/dl by comparison 
with the International Standard for FVIII and von Willebrand Factor (National Institute for 
Biological Standards and Control, Potters Bar, Herfordshire, UK). Factor VII clotting 
activity was measured using Factor VII-deficient plasma (Diagnostica Stago) and Neoplastin 
CI+ (Diagnostica Stago) and expressed as International Units per deciliter (IU/dl) by 
comparison with the International Standard for FVII (National Institute for Biological 
Standards and Control). APTT was measured via the STA-PTT A kit (Diagnostica Stago) 
using silica as an activator. Fibrinogen levels were determined using the STA-Fibrinogen kit 
(Diagnostica Stago) based on the clotting method outlined by Clauss.18 VWF antigen was 
measured by ELISA using polyclonal antiserum (Diagnostica Stago) and expressed as IU/dl 
by comparison with the International Standard for FVIII and VWF (National Institute for 
Biological Standards and Control). ABO serotype was determined using the reverse-typing 
method with A1 and B Referencells (Immucor, Norcross, Georgia, USA).
Anthropometric, Health Status, and Lifestyle Variables
Anthropometric variables (e.g. sex, race, and age), health status variables (e.g. hypertension 
diagnosis, recent surgery, and cancer diagnosis), and life style variables (e.g. annual 
household income, alcohol consumption, and smoking status) were derived from responses 
to questions on a questionnaire administered by trained interviewers.
Statistical Analyses
All analyses were conducted using SAS Version 9.2 (SAS Institute, Cary, North Carolina, 
USA). Race specific abnormal levels of FVIII were defined as FVIII >200 IU/dl for Blacks 
and FVIII >150 IU/dl for Whites.16 High VWF levels were defined as VWF >150 IU/dl. 
High levels of fibrinogen were defined as fibrinogen >4 g/L. Chi-square and Student t tests 
were used to assess the statistical significance of variations in the distribution of 
anthropometric, clinical, health status, and lifestyle characteristics by protein level. Because 
cases and controls were matched on age and sex, conditional logistic regression, 
conditioning on these variables, was used to assess the statistical significance of variations 
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in the distribution of anthropometric, clinical, health status, and lifestyle characteristics by 
VTE case status. Variables such as BMI, FVII level, and APTT were assessed as continuous 
variables in these conditional logistic regression models. Adjusted odds ratios associated 
with high protein levels were estimated using conditional logistic regression, controlling for 
variables independently associated with risk of VTE as well as FVIII, VWF, and/or 
fibrinogen. The initial models included all variables that we judged as potential confounders. 
The final models were more parsimonious models that gave an effect estimate within 10% 
of the estimate from the full model and yielded the greatest average precision. These models 
included the following variables: FVIII, VWF, and/or fibrinogen as well as ABO type, FVII, 
hypertension diagnosis, hyperthyroid disease diagnosis, kidney disease diagnosis, recent 
surgery, diabetes diagnosis, income, and alcohol use. Statistical significance was assessed at 
the α=0.05 level of significance.
Results
Out of 1145 enrolled cases, 256 were eligible for this study (51 reported being a race other 
than Black or White and 889 did not return to the CDC laboratory for blood specimen 
collection after completion of anticoagulant therapy). Of the 256 eligible VTE cases, 152 
cases were considered provoked, and 104 cases were considered idiopathic. The mean time 
between VTE event and return to CDC laboratory for testing was 10.5 (± 6.0) months. Out 
of the 1309 enrolled controls, 1242 were eligible for this study (45 reported being a race 
other than Black or White and 67 did not have a blood specimen). There were 667 White 
and 575 Black controls and 140 White and 116 Black cases eligible for the study. The mean 
FVIII, VWF, and fibrinogen levels for White controls were 142.3 IU/dl, 130.9 IU/dl, and 3.4 
g/L, respectively. Whereas the mean FVIII, VWF, and fibrinogen levels for Black controls 
were 168.3 IU/dl, 149.0 IU/dl, and 3.7 g/L, respectively. The mean FVIII, VWF, and 
fibrinogen levels for White cases were 179.7 IU/dl, 162.5 IU/dl, and 3.8 g/L, respectively. 
The mean FVIII, VWF, and fibrinogen levels for Black cases were 209.4 IU/dl, 195.8 IU/dl, 
and 3.9 g/L, respectively. There was no statistically-significant difference in the mean FVIII 
(183.6 IU/dl vs 177.5 IU/dl, p=0.61), VWF (163.4 IU/dl vs 162.0 IU/dl, p=0.92), or 
fibrinogen (3.79 g/L vs 3.78 IU/dl, p=0.93) levels measured in White idiopathic VTE cases 
compared to White provoked VTE cases. Similarly, there was no statistically-significant 
different in the mean FVIII (213.4 IU/dl vs 205.8 IU/dl, p=0.56), VWF (193.4 IU/dl vs 
198.0 IU/dl, p=0.78), or fibrinogen (3.79 g/L vs 3.97 g/L, p=0.28) levels measured in Black 
idiopathic cases compared to Black provoked cases.
Covariates that were found to be independent predictors of VTE are shown in Table 1. The 
strongest independent predictors of VTE risk included cancer diagnosis, renal disease 
diagnosis, and recent surgery. The variables shown in Table 1 were used in the full model to 
estimate adjusted odds ratios for risk of VTE.
Crude odds ratios for odds of VTE in patients with high protein levels compared to those 
with low protein levels are shown in Table 2. Before adjustment for independent predictors 
of VTE risk, high levels of FVIII, VWF, and fibrinogen were significantly associated with 
increased risk of VTE in both Blacks and Whites. Furthermore, combinations of high protein 
levels tended to be associated with greater increased risk of VTE, particularly for Whites. 
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However, after adjustment for ABO type, FVII levels, hypertension, kidney disease, recent 
surgery, diabetes, annual household income, alcohol use, and other proteins of interest 
(FVIII, VWF, and/or fibrinogen) (Table 2) several associations were no longer significant. 
High FVIII and VWF were associated with increased risk of VTE in Blacks (OR: 1.97 
(1.01-3.84) and 3.39 (1.58-7.27), respectively), with high levels of both proteins conferring 
even greater risk (OR: 4.20 (2.24-7.89)). High fibrinogen was no longer associated with 
significantly increased risk of VTE in Blacks (OR: 1.38 (0.75-2.54). High FVIII was the 
only protein level significantly associated with risk of VTE in Whites (OR: 2.35 
(1.16-4.75)).
Discussion
The objective of this study was to assess the association of FVIII, VWF, and fibrinogen 
levels and risk of VTE and to assess any differences in risk by race. Previous studies have 
implicated high FVIII, VWF, and fibrinogen levels as risk factors for VTE, with high FVIII 
levels being more consistently associated with increased risk.8-12,14,19 However, many of 
these studies only adjusted for age and sex and failed to adjust for other covariates that 
impact both factor level and risk of VTE. We have used logistic regression models to control 
for such confounders and in doing so have eliminated high fibrinogen and VWF levels as 
risk factors for VTE in Whites. Both FVIII and VWF, however, remain independent 
predictors of risk for VTE in Blacks. While FVIII, VWF, and fibrinogen levels are related, 
controlling for levels of the proteins when assessing the effect of high levels of the other 
proteins allowed the assessment of the independent contribution of each protein to risk of 
VTE.
Recent publications have suggested the mechanism conferring VTE risk for high FVIII 
levels relates to constitutively high levels as opposed to spikes in levels, as is the case with 
the acute-phase response.20,21 Our findings agree with these results. After controlling for 
variables likely implicated in acute-phase response (e.g., diabetes diagnosis and recent 
surgery), we find high levels of FVIII remain an independent risk factor for VTE in both 
Blacks and Whites. Furthermore, after controlling for FVIII and VWF levels as well as other 
variables implicated in the acute-phase response, fibrinogen (a marker of the acute-phase 
response) is no longer associated with risk of VTE.
This report is the first to suggest that high VWF levels are associated with risk of VTE in 
Blacks only. Reports have suggested certain polymorphisms in the gene coding VWF are 
related to levels of VWF and that the distribution of these polymorphisms differs by race.22 
Perhaps these polymorphisms also confer increased risk for VTE and help explain the 
differing results between Blacks and Whites in our population. Future studies are needed to 
assess this relationship. However, if these findings hold, high levels of VWF as a risk factor 
for VTE in Blacks may help explain some of the racial disparity in risk of VTE and could 
prove an important risk factor to assess in the clinical setting.
Because traditional diagnostic techniques for VTE fail to implicate an underlying inherited 
or acquired prothrombotic tendency in up to 50% of patients4, identification of novel risk 
factors such as FVIII, VWF, or fibrinogen levels could aid in the identification of patients 
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at-risk for developing VTE before the event occurs. The findings in this report suggest 
measurement of FVIII activity could be considered when assessing VTE risk clinically in 
Whites and that both FVIII and VWF levels could be considered when assessing risk in 
Blacks. However, more work regarding the predictive value of these measurements is 
necessary before recommending the tests be used routinely in clinical settings.
The strengths of this study include its relatively large sample of VTE cases and controls and 
its ability to control for likely confounders of the association between FVIII, VWF, and 
fibrinogen levels and risk of VTE. A weakness of this study is the high rate of lost to follow-
up for cases. A number of cases did not return to the CDC laboratory after completion of 
anticoagulant therapy for blood sample collection, possibly resulting in a biased case group. 
However, comparison of key indicators of health collected in the study questionnaire and 
completed by all cases indicates those who returned for blood sample collection were not 
significantly different than those cases who did return (Table 3). Another limitation of this 
study is the timing of procoagulant protein measurement. VTE cases were identified prior to 
enrollment in the study, and procoagulant proteins were measured subsequent to enrollment. 
In order to prevent measurement bias, we required all cases to complete anticoagulant 
therapy before blood sample collection. However, it is possible levels of FVIII, VWF, or 
fibrinogen may differ before and after a biologically stressful event such as VTE. This report 
assumes ample time between event and measurement allowed for the return to of these 
proteins basal levels.
The results of this study indicate that high levels of FVIII and VWF are independent risk 
factors for VTE in Blacks and high levels of FVIII are a risk factor for VTE in Whites. After 
accounting for likely confounders, high fibrinogen levels were not a risk factor for VTE in 
this population. Future research into the inclusion of FVIII and VWF levels in risk models 
for VTE could help define those at highest risk for an event and could help explain some of 
the racial disparity in risk of VTE between Blacks and Whites.
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BMI (kg/m2) 116 575 0.98 0.47 140 666 1.07 <0.01*
ABO Type
O 43 43 1.00 - 44 286 1.00 -
A 30 158 1.14 0.62 71 272 1.70 0.01*
B 123 123 1.76 0.02* 21 80 1.71 0.07
AB 3 27 0.70 0.57 2 23 0.60 0.50
FVII (%) 116 575 1.00 0.01* 140 667 1.00 <0.01*
APTT (s) 116 575 0.89 <0.01* 140 667 0.94 0.05*
Hypertension
Yes 51 268 0.91 0.68 65 192 2.10 <0.01*
No 65 307 75 475
Hyperthyroid Disease
Yes 1 18 0.26 0.19 8 15 2.54 0.04*
No 114 557 130 652
Infection
Yes 18 17 6.14 <0.01* 28 40 4.08 <0.01*
No 92 558 110 627
Malignancy
Yes 9 2 26.19 <0.01* 12 4 16.22 <0.01*
No 107 573 128 663
Renal Disease
Yes 15 8 9.80 <0.01* 6 4 6.98 <0.01*
No 101 566 134 662
Surgery
Yes 34 10 23.84 <0.01* 70 17 36.28 <0.01*
No 82 565 70 650
Diabetes
Yes 24 89 1.47 0.15 21 41 2.52 <0.01*
No 92 486 119 626
Annual Household
Income <$55,000
Yes 82 371 1.46 0.11 59 186 2.31 <0.01*
No 30 202 76 478
Education Attainment
< Junior College
Yes 75 343 1.22 0.36 69 181 2.77 <0.01*
No 41 232 71 486






























Yes 106 438 3.48 <0.01* 115 312 5.35 <0.01*
No 10 137 25 355
Physical Activity 116 575 1.00 0.89 140 667 0.99 <0.01*
(%hours sitting/week)
†
Conditioned on age and sex
*
Significant at the α=0.05 level of significance


















Crude OR† Adjusted OR††
























High FVIII, VWF and 
Fibrinogen




Table 2a: Crude and adjusted associations of protein levels with risk of VTE in Blacks
†Conditioned on age and sex
††Conditioned on age and sex and controlling for FVIII, VWF, and/or fibrinogen, ABO type, FVII, hypertension diagnosis, hyperthyroid 
disease diagnosis, kidney disease diagnosis, recent surgery, diabetes diagnosis, income, and alcohol use





Crude OR† Adjusted OR††
























High FVIII, VWF and 
Fibrinogen




Table 2b: Crude and adjusted associations of protein levels with risk of VTE in Whites
†
Conditioned on age and sex
††
Conditioned on age and sex and controlling for FVIII, VWF, and/or fibrinogen, ABO type, FVII, hypertension diagnosis, hyperthyroid disease 
diagnosis, kidney disease diagnosis, recent surgery, diabetes diagnosis, income, and alcohol use
*
Significant at the α=0.05 level of significance
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White, n(%) 557 (50.9%) 140 (54.7%) 0.31
Black, n(%) 537 (49.1%) 116 (45.3%)
Age, mean 48.7 years 49.9 years 0.16
Sex
Female, n(%) 576 (50.3%) 126 (49.2%) 0.75
Male, n(%) 569 (49.7%) 130 (50.8%)
Diabetes
No, n(%) 907 (79.2%) 211 (82.4%) 0.25
Yes, n(%) 238 (20.8%) 45 (17.6%)
Hypertension
No, n(%) 633 (55.3%) 140 (54.7%) 0.85
Yes, n(%) 511 (44.6%) 116 (45.3%)
Alcohol Consumption
>20 Drinks/Week, n(%) 6 (0.5%) 1 (0.4%) 0.61
8-20 Drinks/Week, n(%) 26 (2.3%) 7 (2.7%)
1-7 Drinks/Week, n(%) 114 (10.0%) 27 (10.6%)
<1 Drink/Week, n(%) 116 (10.1%) 34 (13.3%)
Rarely/Never, n(%) 882 (77.1%) 187 (73.1%)
Case Type
Deep Vein Thrombosis Only 691 (60.5%) 166 (64.8%) 0.20
Pulmonary Embolism Only 232 (20.3%) 53 (20.7%)
Deep Vein Thrombosis and Pulmonary Embolism 219 (19.2%) 37 (14.5%)
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